Australia markets open in 6 hours 17 minutes
  • ALL ORDS

    7,707.20
    +102.00 (+1.34%)
     
  • AUD/USD

    0.7165
    +0.0047 (+0.66%)
     
  • ASX 200

    7,405.40
    +91.50 (+1.25%)
     
  • OIL

    72.47
    +0.42 (+0.58%)
     
  • GOLD

    1,783.00
    -1.70 (-0.10%)
     
  • BTC-AUD

    70,248.71
    -2,104.76 (-2.91%)
     
  • CMC Crypto 200

    1,310.27
    +5.15 (+0.39%)
     

SHAREHOLDER ACTION ALERT: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against Amarin Corporation, plc and Encourages Investors with Losses in Excess of $500,000 to Contact the Firm

·2-min read

LOS ANGELES, October 26, 2021--(BUSINESS WIRE)--The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Amarin Corporation, plc ("Amarin" or "the Company") (NASDAQ: AMRN) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.

Investors who purchased the Company's securities between December 5, 2018, and June 21, 2021, inclusive (the ''Class Period''), are encouraged to contact the firm before December 23, 2021.

If you are a shareholder who suffered a loss, click here to participate.

We also encourage you to contact Brian Schall of the Schall Law Firm, 2049 Century Park East, Suite 2460, Los Angeles, CA 90067, at 310-301-3335, to discuss your rights free of charge. You can also reach us through the firm's website at www.schallfirm.com, or by email at brian@schallfirm.com.

The class, in this case, has not yet been certified, and until certification occurs, you are not represented by an attorney. If you choose to take no action, you can remain an absent class member.

According to the Complaint, the Company made false and misleading statements to the market. (i) There was an increasingly high risk that certain of Amarin’s patents would be invalidated; (ii) once certain of Amarin’s patents were invalidated by the United States District Court for the District of Nevada, there was little to no chance of reversing that ruling; (iii) the Company’s litigation was preventing it from effectuating a successful takeover; (iv) Defendants were downplaying the true threat the ongoing Abbreviated New Drug Application ("ANDA") litigation posed to the Company’s business and future prospects; and (v) as a result, the Company’s public statements were materially false and misleading at all relevant times. When the market learned the truth about Amarin, investors suffered damages.

Join the case to recover your losses.

The Schall Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.

View source version on businesswire.com: https://www.businesswire.com/news/home/20211026005875/en/

Contacts

The Schall Law Firm
Brian Schall, Esq.
www.schallfirm.com
Office: 310-301-3335
info@schallfirm.com

Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting